Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
Propelled by Covid Pfizer surges ahead, but more interest could fall on a cohort of companies driven by newcomer drugs lower down the list.
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
The approval is good for CSL, and better for Uniqure.